Eagle Pharmaceuticals Inc chart

Last update: 2022-12-30
Key statistics and financials
Revenue per share 23.11
Dividend & YieldN/A$ (N/A)
Beta 0.8
Market capitalization 458.81M
Operating cash flow 21.23M
ESG Scores unknown

Company description

Eagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin's lymphoma. Its product candidates also include EP-4104, a dantrolene sodium to treat organophosphate exposure; PEMFEXY, a ready-to-use/dilute liquid form of pemetrexed for non-small cell lung cancer and mesothelioma; EA-114 (fulvestrant) for HR+/HER- breast cancer; and Vasopressin injection, which is indicated to enhance blood pressure in adults with vasodilatory shock. The company has license and collaboration agreements with Combioxin, SA for the development and commercialization rights to CAL02, an antitoxin agent for the treatment of severe pneumonia in combination with traditional antibacterial drugs; and AOP Orphan Pharmaceuticals GmbH for the commercial rights of Landiolol, a novel therapeutic product candidate for the short-term reduction of ventricular rate in patients with supraventricular tachycardia, including atrial fibrillation and atrial flutter. It has a strategic collaboration with Tyme Technologies, Inc. for the development of SM-88 to treat breast cancer (HR+/HER2-) and high-risk metastatic sarcomas. Eagle Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Woodcliff Lake, New Jersey.

Sector: Healthcare - Industry: Drug Manufacturers—Specialty & Generic

Financial data

Financial Statements

Cashflow Statement 2018-12-31 2019-12-31 2020-12-31 2021-12-31
Change To Liabilities -2.06M -4.46M 806k 10.16M
Total Cashflows From Investing Activities -133k -777k -18.25M -5.32M
Net Borrowings -3.75M -6M -5M -8M
Total Cash From Financing Activities -88.12M -24.23M -37.87M -28.39M
Change To Operating Activities 12.4M -1.37M 4.63M 3.68M
Issuance Of Stock 8.62M 260k 3.65M 2.4M
Net Income 31.9M 14.31M 11.99M -8.63M
Change In Cash -35.87M 30.98M -6.62M -5.5M
Effect Of Exchange Rate
Total Cash From Operating Activities 52.38M 55.99M 49.5M 28.22M
Depreciation 3.67M 4.65M 4.77M 4.81M
Change To Account Receivables -12.66M 18.48M -3.11M 9.53M
Other Cashflows From Financing Activities -19.88M -326k
Change To Netincome 24.32M 22.15M 31.51M 22.03M
Capital Expenditures -133k -777k -747k -323k

Income Statement 2018-12-31 2019-12-31 2020-12-31 2021-12-31
Research Development 44.42M 36.81M 30.79M 51.27M
Income Before Tax 34.04M 22M 22.68M -4.55M
Net Income 31.9M 14.31M 11.99M -8.63M
Selling General Administrative 60.51M 76.37M 78.6M 75.32M
Gross Profit 151.4M 135M 142.34M 129.37M
Ebit 46.47M 21.82M 32.95M 2.77M
Operating Income 46.47M 21.82M 32.95M 2.77M
Interest Expense -2.74M -2.69M -2.58M -1.64M
Income Tax Expense 2.13M 7.68M 10.69M 4.08M
Total Revenue 213.31M 195.89M 187.8M 171.55M
Cost Of Revenue 61.92M 60.9M 45.47M 42.18M
Total Other Income ExpenseNet -11.67M 183k -10.28M -7.32M
Net Income From Continuing Ops 31.9M 14.31M 11.99M -8.63M
Net Income Applicable To Common Shares 31.9M 14.31M 11.99M -8.63M

Balance Sheet Statement 2018-12-31 2019-12-31 2020-12-31 2021-12-31
Total Liabilities 77.84M 75.38M 67.18M 77.28M
Total Stockholder Equity 160.76M 179.17M 186.01M 176.45M
Other Current Liabilities 1.95M 6.97M
Total Assets 238.6M 254.55M 253.19M 253.73M
Common Stock 17k 17k 17k 17k
Other Current Assets 8.57M 8.57M 2.27M 5.27M
Retained Earnings 58.19M 72.5M 84.49M 75.86M
Treasury Stock -153.9M -171.86M -203.9M -225.21M
Cash 78.79M 109.78M 103.16M 97.66M
Total Current Liabilities 39.69M 38.82M 38.09M 74.38M
Other Stockholder Equity -94k
Property, Plant, and Equipment 2.4M 2.2M 2.08M 1.64M
Total Current Assets 163.84M 179.45M 166.06M 172.61M
Net Tangible Assets 102.92M 123.85M 133.35M 126.04M
Net Receivables 66.49M 48M 51.12M 46.46M
Accounts Payable 9.92M 5.46M 6.27M 16.43M


Insider Transactions

Here are the insider transactions of stock shares related to Eagle Pharmaceuticals Inc:

Filer Name Transaction Text Ownership Date Filer Relation Shares
EDLIN RICHARD ASale at price 30.99 per share.D2022-09-06Director6.8k
TARRIFF SCOTT LStock Award(Grant) at price 0.00 per share.D2022-02-28Chief Executive Officer34.8k
CAHILL BRIAN JOSEPHStock Award(Grant) at price 0.00 per share.D2022-02-28Chief Financial Officer8k
MORAN MICHAEL SHAWNStock Award(Grant) at price 0.00 per share.D2022-02-28Officer10.4k
RATOFF STEVEN BConversion of Exercise of derivative security at price 4.42 - 8.78 per share.D2021-04-08Director7.02k
TARRIFF SCOTT LConversion of Exercise of derivative security at price 8.78 per share.D2021-04-01Chief Executive Officer31.2k
TARRIFF SCOTT LStock Gift at price 0.00 per share.D2021-02-23Chief Executive Officer16.34k
PERNOCK DAVIDStock Award(Grant) at price 0.00 per share.D2021-02-02President9.7k
NG-CASHIN JUDITHStock Award(Grant) at price 0.00 per share.D2021-02-02Officer2k
CAHILL BRIAN JOSEPHStock Award(Grant) at price 0.00 per share.D2021-02-02Chief Financial Officer8.9k
CAHILL BRIAN JOSEPHStock Award(Grant) at price 0.00 per share.D2020-12-18Chief Financial Officer5k

Insider transaction explanations

Insider buying is the legal purchase of shares by a senior executive or director of a company. "Filer Name" corresponds to the name of the stock buyer or seller. "Transaction Text" describes the transaction. "Ownership" gives information about the transaction type. "Date" is the reported transaction date. "Filer Relation" gives the role of the insider in the company. "Shares" is the value of the transaction. You will find the complete description of the General Transaction Codes on the SEC dedicated page


Investment strategy backtesting

These are the result of three automatic investment systems applied to Eagle Pharmaceuticals Inc. You will find the performance of an systematic investment system, a momentum strategy, and a buy the dip trading strategy.


Systematic investment results on Eagle Pharmaceuticals Inc

Here is the result of two systematic investment strategies applied to Eagle Pharmaceuticals Inc. The first strategy automatically buys the first day of the month, and the second strategy buys the fifteenth day of the month.

Systematic investment equity curve on Eagle Pharmaceuticals Inc

The following chart shows the equity curve of the two systematic investment strategies applied to Eagle Pharmaceuticals Inc:

Eagle Pharmaceuticals Inc automated entries

The systematic investment strategy that buys the first day of the month would give a performance of 3.83% on the backtest period.

Performance at glance

Performance

3.83 %

Latent gain

66.92 $

Invested capital

1746.43 $

Annualized return

0.93 %
Build your Trading System
Automated Trading using Prorealtime ebook

Momentum strategy results on Eagle Pharmaceuticals Inc

This is the result of two momentum investment strategies applied to Eagle Pharmaceuticals Inc. The first strategy uses a momentum signal calculated on one quarter, and the second uses a momentum signal calculated on two quarters.

Momentum entry openings on Eagle Pharmaceuticals Inc

The following chart shows all the entries opened by the momentum investment system on Eagle Pharmaceuticals Inc:

Eagle Pharmaceuticals Inc momentum entries
  • The first momentum investment strategy would give 7.03% of return on Eagle Pharmaceuticals Inc. That represents 404.83$ of latent gain with 5760.56$ of employed capital.
  • The second momentum investment strategy would give 4.64% of return on Eagle Pharmaceuticals Inc. That represents 128.53$ of latent gain with 2772.83$ of employed capital.
Performance at glance (1Q Momentum)

Performance

7.03 %

Latent gain

404.83 $

Invested capital

5760.56 $

Annualized return

13.94 %
Performance at glance (2Q Momentum)

Performance

4.64 %

Latent gain

128.53 $

Invested capital

2772.83 $

Annualized return

1.28 %

Momentum equity curve on Eagle Pharmaceuticals Inc

The following chart shows the equity curve of the two momentum strategies applied to Eagle Pharmaceuticals Inc:

Eagle Pharmaceuticals Inc momentum equity

Note: the dividends potentially given by Eagle Pharmaceuticals Inc are not integrated into the calculation of the equity curve neither the performance of the strategy. The integration of the dividends will be available soon.


Employed capital on Eagle Pharmaceuticals Inc

The following chart shows the employed capital evolution of the two momentum strategies on Eagle Pharmaceuticals Inc since the beginning:

Eagle Pharmaceuticals Inc

Note: the algorithm buys for a maximum of 250$ per entry. If the stock price is greater than 250$, the system buys only one stock per entry. The investment system stops automatically when the financial exposure reaches 10000$.


Buy the dip strategy result on Eagle Pharmaceuticals Inc

Buy the dip entry openings on Eagle Pharmaceuticals Inc

Eagle Pharmaceuticals Inc

The performance achieved by the robo-advisor on Eagle Pharmaceuticals Inc is 29.27%. That represents 140.76$ of latent gain with 480.96$ of employed capital. The following chart shows Eagle Pharmaceuticals Inc stock price with all the entries opened by the automated investment system.

Note: The blue line represents the weekly stock price of Eagle Pharmaceuticals Inc, and the green triangles represent the entry openings. The artificall robo-advisor needs at least 100 weeks of trading history to work.

Performance at glance

Performance

29.27 %

Latent gain

140.76 $

Invested capital

480.96 $

Annualized return

13.94 %

Equity curve of the strategy applied to Eagle Pharmaceuticals Inc

The following chart shows the result of the investment strategy applied to Eagle Pharmaceuticals Inc:

Eagle Pharmaceuticals Inc

Note: the dividends potentially given by Eagle Pharmaceuticals Inc are not integrated into the calculation of the equity curve neither the performance of the strategy. The integration of the dividends will be available soon.


Employed capital on Eagle Pharmaceuticals Inc

The following chart shows the employed capital evolution since the beginning of the investment strategy on Eagle Pharmaceuticals Inc:

Eagle Pharmaceuticals Inc

Note: the algorithm buys for a maximum of 250$ per entry. If the stock price is greater than 250$, the system buys only one stock per entry. The investment system stops automatically when the financial exposure reaches 10000$.


Investment strategies comparison on Eagle Pharmaceuticals Inc

In this section, I will compare the three previous investment strategies applied to Eagle Pharmaceuticals Inc.

Equity curve comparison on Eagle Pharmaceuticals Inc

The following chart shows the equity curve of the artificall advisor, the trend folowing and the automatic investment strategies:

Eagle Pharmaceuticals Inc investment strategy comparison

Employed capital comparison on Eagle Pharmaceuticals Inc

Eagle Pharmaceuticals Inc investment comparison

Performance comparison on Eagle Pharmaceuticals Inc

Strategy Latent Profit Growth Employed capital CAGR
Automatic investment 3.83% 66.92$ 1746.43$ 0.93%
Momentum 1 quarter 7.03% 404.83$ 5760.56$ 1.82%
Momentum 2 quarters 4.64% 128.53$ 2772.83$ 1.28%
Non-directional 29.27% 140.76$ 480.96$ 13.94%
Annualized return comparison

Automatic investment

0.93 %

Momentum 1Q

1.28 %

Momentum 2Q

1.28 %

Non-directional

13.94 %

Correlated stocks

Here are the most positively and negatively correlated stocks with Eagle Pharmaceuticals Inc:

Positive correlations

Most correlated stocks this year

  • Eagle Pharmaceuticals Inc

  • Most correlated stocks last 3 months

  • Eagle Pharmaceuticals Inc
  • ASIAN
  • SAMSE

  • Negative correlation

    Most negatively correlated stocks this year


    Most negatively correlated stocks last 3 months


    Note: The algorithm computes the probability of correlation between Eagle Pharmaceuticals Inc and the other stocks. There may be false positives or some missing correlated stocks. If the price of Eagle Pharmaceuticals Inc does not vary for 36 weeks, the correlation calculation result will be wrong.


    Company information

    Company name Eagle Pharmaceuticals Inc
    Country United States
    City Woodcliff Lake
    Address 50 Tice Boulevard
    Phone 201 326 5300
    Website www.eagleus.com
    FullTime employees 114
    Industry Drug Manufacturers—Specialty & Generic
    Sector Healthcare
    Exchange XNAS
    Ticker EGRX
    Market www.nasdaq.com

    Eagle Pharmaceuticals Inc ESG Scores

    Environment scores

    Environment ESG Factors Scores
    Environment Score 0
    Peer Environment Performance unknown
    Environment Percentile unknown
    Palm Oil unknown
    Nuclear unknown
    Fur Leather unknown
    GMO unknown
    Coal unknown
    Pesticides unknown
    Animal Testing unknown

    Social scores

    Social ESG Factors Scores
    Social Score 0
    Peer Social Performance unknown
    Social Percentile unknown
    Highest Controversy unknown
    Peer Highest Controversy Performance unknown
    Adult unknown
    Gambling unknown
    Alcoholic unknown
    Tobacco unknown
    Catholic unknown
    Controversial Weapons unknown
    Small Arms unknown
    Military Contract unknown
    Peer Count unknown

    Related Controversy:


    Governance scores

    Governance ESG Factors Scores
    Governance Score 0
    Peer Governance Performance unknown
    Governance Percentile unknown

    ESG at glance
    Total ESG Scores: unknown
    Environment Score: 0
    Social Score: 0
    Governance Score: 0

    ESG Performance: unknown

    Peer Group: unknown

    Peer Esg Score Performance: unknown

    Rating Year: unknown

    Rating Month: unknown

    Max Age: unknown

    Percentile: unknown